In PROLUNG trial, which compared the therapeutic efficacy of pembrolizumab plus docetaxel versus docetaxel alone in pretreated NSCLC patients, 25 patients with EGFR mutations were enrolled. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.